The whole-exome sequencing and whole-transcriptome sequencing-based test is approved for molecular profiling of solid tumors.

Here are five top dividend stocks, including two Dividend Kings, that nervous investors should consider now for passive ...

Charting, Price Performance, News & Related Contracts.

On Oct. 29, Pfizer PFE announced third-quarter results, beating estimates for earnings as well as sales. Revenues rose 32% on ...

Operator Good day, everyone, and welcome to Pfizer's third quarter 2024 earnings conference call. Today's call is being ...

Reports Q3 revenue $17.7B, consensus $14.95B. Dr. Albert Bourla, Chairman and Chief Executive Officer, stated: “We delivered another ...

Despite today's fall in Pfizer's share price, it beat my and Wall Street analysts' expectations for Q3 by a large margin. See ...

Pfizer's oncology revenues jumped 30 percent in the third quarter, with growth from several precision oncology drugs.

Pfizer Inc. (NYSE: PFE) has reported a robust financial performance for the third quarter of 2024, showcasing significant ...

Pfizer (NYSE:PFE) shares climbed around 2% in premarket trading Tuesday after the pharma giant raised earnings and revenue guidance for fiscal 2024 and beat Q3 results estimates.

Here are six high-yield dividend stocks that growth and income investors may want to consider as interest rates head lower.